Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1996-04-18
1999-02-02
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241471, 4243913, 4351723, 536 2353, A61K 39395, A61K 3942, C12N 1500, C07H 2104
Patent
active
058661255
ABSTRACT:
A method of obtaining high affinity human monoclonal antibodies having a Kd of .ltoreq.2.times.10.sup.-9 molar in SCID mice is provided.
REFERENCES:
patent: 4517304 (1985-05-01), Stott et al.
patent: 4659563 (1987-04-01), Dobkin
patent: 4717766 (1988-01-01), Dobkin
patent: 4760026 (1988-07-01), Lennox et al.
patent: 4800078 (1989-01-01), Prince et al.
patent: 4853326 (1989-08-01), Quash et al.
patent: 5071758 (1991-12-01), Stott et al.
patent: 5137804 (1992-08-01), Greene et al.
patent: 5149650 (1992-09-01), Wertz et al.
patent: 5183657 (1993-02-01), Buurman
patent: 5194595 (1993-03-01), Wathen
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 5223254 (1993-06-01), Paradiso et al.
patent: 5240694 (1993-08-01), Gwaltney, Jr.
patent: 5271927 (1993-12-01), Parker et al.
patent: 5279935 (1994-01-01), Nycz
patent: 5288630 (1994-02-01), Wathen
patent: 5290540 (1994-03-01), Prince et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5332805 (1994-07-01), Carey et al.
patent: 5340926 (1994-08-01), Lowe et al.
patent: 5354554 (1994-10-01), Rhind
patent: 5391478 (1995-02-01), Greene et al.
patent: 5412077 (1995-05-01), Siber et al.
patent: 5418136 (1995-05-01), Miller et al.
patent: 5422097 (1995-06-01), Gwaltney, Jr.
patent: 5424189 (1995-06-01), Oberst et al.
patent: 5468606 (1995-11-01), Bogart et al.
patent: 5470736 (1995-11-01), Verma et al.
patent: 5484893 (1996-01-01), Parker et al.
patent: 5506209 (1996-04-01), Mukerji et al.
patent: 5518725 (1996-05-01), Daynes et al.
patent: 5530102 (1996-06-01), Gristina et al.
patent: 5534411 (1996-07-01), Weltzin
patent: 5538733 (1996-07-01), Emery et al.
patent: 5538952 (1996-07-01), Mukerji et al.
Trudel et al., Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection, Arch Virol 117:59-71, see connecting paragraphs, pp. 61-62 and 64-65, 1991.
Zhang et al., Soluble Factor-Independent Stimulation of Human B Cell Response by Mouse Thymoma Cells, J. Immunol., 144, 2955-2960, 1990.
Mosier et al., Transfer of a functional human immune system to mice with severe combined immunodeficiency, Nature, 335: 256-259, 1988.
McCune et al., The SCID-hu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and Function, Science, 241, 1632-1639, 1988.
Gorny et al, Generation of human monoclonal antibodies to human immunodeficiency virus, PNAS, 86: 1624-1628, see Abstract, 1989.
Kozbor et al., Requirements for the establishment of high-titered human monoclonal antibodies against tetnus toxoid using the Epstein-Barr virus technique, J. Immunol., 127, 1275-1280, see Abstract, 1981.
Paul W., E., 1993, Fundamental Immunology, p. 242.
Seaver, 1994, Genetic Engineering News, vol. 14(14), pp.10+21.
Brams Peter
Chamat Soulaima Salim
Heard Cheryl Janne
Newman Roland Anthony
Pan Li-Zhen
Achutamurthy Ponnathapura
Idec Pharmaceuticals Corporation
Park Hankyel T.
LandOfFree
Neutralizing high affinity human monoclonal antibodies specific does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing high affinity human monoclonal antibodies specific , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing high affinity human monoclonal antibodies specific will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1114588